TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17065044
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Fe 30 mg and folic acid 400 microg)
Study: 12562405
Drug: Recruitment group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruitment group (pressure-controlled stepwise increase in PEEP up to 15 cmH2O and tidal volumes of up to 18 ml x kg(‐1) for 10 cycles)
Study: 10365012
Drug: Test 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test 2: Detection of end-tidal carbon dioxide in the oral cavity
Study: 8713637
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Xylocaine 1 mg.Kg‐1 followed by Propofol 2 mg.Kg‐1 over 20 seconds
Study: 8713637
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Xylocaine 1 mg.Kg‐1 and Fentanyl 1.5 ug.Kg‐1 followed by Propofol 2 mg.Kg‐1 over 20 seconds
Study: 8713637
Drug: Fentanyl 1.5
Normalized name: fentanyl 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.5 ug.Kg‐1 with Propofol 2 mg.Kg‐1
Study: 2051364
Drug: Post-treatment performance
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment performance scores at 60 months
Study: 6343091
Drug: Misonidazole (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole (1.3 g/m2, administered 4 hr before the first 9 irradiations)
Study: 31355956
Drug: Voriconazole +
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole + Anidulafungin (combination therapy)
Study: 31355956
Drug: Voriconazole +
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole + Placebo (monotherapy)
Study: 25944414
Drug: Mepivacaine-tramadol combination
Normalized name: mepivacaine, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine-tramadol combination (1.3 mL of 2% mepivacaine with epinephrine 1:100,000 plus 0.5 mL of tramadol 50 mg/mL)
Study: 25944414
Drug: Mepivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine alone (1.8 mL of 2% mepivacaine with epinephrine 1:100,000)
Study: 25944414
Drug: Mepivacaine-tramadol combination
Normalized name: mepivacaine, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine-tramadol combination
Study: 23038043
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg eszopiclone
Study: 23038043
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg eszopiclone
Study: 23038043
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg eszopiclone (multiple-dose)
Study: 12127923
Drug: Extended dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended dalteparin treatment (5000 or 7500 IU.12h(‐1) to day 90)
Study: 12127923
Drug: Extended dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended dalteparin treatment
Study: 12127923
Drug: Acute treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment with dalteparin (120 IU/kg(‐1) 12h(‐1) for 5-7 days)
Study: 7594324
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg daily for 8 weeks (gastric ulcers) or 6 weeks (duodenal ulcers)
Study: 7594324
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg daily for 8 weeks (gastric ulcers) or 6 weeks (duodenal ulcers) plus amoxicillin 2 g daily for 2 weeks
Study: 2041279
Drug: Captopril (C)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (C) 50 mg
Study: 2041279
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ID) 10 mg
Study: 2041279
Drug: Nifedipine (N)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (N) 20 mg
Study: 18499588
Drug: Transdermal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oxygen delivery using 2 EpiFlo oxygen generators providing oxygen at 6 mL/h into an occlusive wound dressing
Study: 16814669
Drug: Acadesine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acadesine (0.1 mg/kg/min; 7 h intravenous infusion and in cardioplegia solution at 5 microg/ml)
Study: 14635629
Drug: New therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: New therapies that are less efficacious but more affordable and feasible than the best current therapeutic standard
Study: 8883528
Drug: iodixanol‐270 (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodixanol‐270 (270 mg I/ml)
Study: 8883528
Drug: iodixanol‐320 (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodixanol‐320 (320 mg I/ml)
Study: 8883528
Drug: iohexol‐300 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol‐300 (300 mg I/ml)
Study: 1578612
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam 4 mg
Study: 1578612
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam 4.5 mg
Study: 1578612
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam 5 mg
Study: 1578612
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of midazolam
Study: 29667199
Drug: Multisensory stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisensory stimulation (MSS) for 4 weeks, 3 sessions weekly, 25 minutes each session
Study: 30541483
Drug: FaME exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: FaME exercise programme, 1 hour weekly for 12 weeks, advised to exercise at home for an additional 2 hours
Study: 27082062
Drug: Dovitinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dovitinib (500 mg/day, 5 days on, 2 days off; n = 82)
Study: 27082062
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg twice daily; n = 83)
Study: 23441902
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of topical calcipotriol, NB-UVB, and betamethasone therapies
Study: 23441902
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NB-UVB and topical calcipotriol
Study: 22612071
Drug: Theophylline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (200 mg in 100 mL 0.9% saline, as IV infusion 30 minutes before contrast medium administration)
Study: 18044544
Drug: DBP exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBP exposure in rats (oral gavage)
Study: 14975457
Drug: COX‐2 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX‐2 inhibitors
Study: 14975457
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with aspirin and other COX inhibitors
Study: 11524482
Drug: 100-mg Dilantin
Normalized name: phenytoin sodium 100 MG [Dilantin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg Dilantin Kapseals after an 8-hour fast
Study: 11524482
Drug: 100-mg Dilantin
Normalized name: phenytoin sodium 100 MG [Dilantin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg Dilantin Kapseals after a high-fat meal
Study: 9272803
Drug: Sucrose alone
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose alone (0.05 ml of 24% sucrose placed on the anterior surface of the tongue just prior to heelstick)
Study: 9272803
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sucrose and simulated rocking
Study: 9272803
Drug: Placebo (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.05 ml sterile water administered just prior to heelstick)
Study: 7506742
Drug: Gabexate mesilate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate, administered within 72 hours of onset of symptoms at a dose of 3 g/24 h
Study: 26983099
Drug: Short-term interactive
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term interactive video games (eight 30-minute sessions) in addition to traditional rehabilitation treatment
Study: 26983099
Drug: Traditional rehabilitation
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional rehabilitation treatment
Study: 21883997
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg o.d.
Study: 9174677
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg b.i.d.
Study: 16765526
Drug: 21‐mg nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21‐mg nicotine patch for 3 months, with a 1‐month taper
Study: 12466693
Drug: Bromelain 300
Normalized name: Bromelain
DrugBank: Bromelains (DB13281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromelain 300 mg t.i.d.
Study: 11548225
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg t.i.d.
Study: 9523811
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg mivacurium in divided doses (0.15 mg/kg followed by 0.1 mg/kg 30 s later)
Study: 9523811
Drug: 1.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg/kg rocuronium
Study: 9523811
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg mivacurium
Study: 8089666
Drug: Bromocriptine (52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (52 mg/day for 2.7 years) followed by levodopa (471 mg/day)
Study: 8089666
Drug: Levodopa alone
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa alone (569 mg/day)
Study: 31221502
Drug: ACT-541468 25
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-541468 25 mg
Study: 31221502
Drug: ACT-541468 25
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-541468 25 mg and 75 mg
Study: 31221502
Drug: ACT-541468 10
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-541468 10 mg
Study: 31221502
Drug: ACT-541468 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-541468 (all doses)
Study: 19890022
Drug: Simvastatin plus
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin plus Metformin (SM)
Study: 21865358
Drug: Simvastatin (S)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (S) and Simvastatin plus Metformin (SM)
Study: 21865358
Drug: Simvastatin (S),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (S), Metformin (M), Simvastatin plus Metformin (SM)
Study: 17407630
Drug: Selegiline ODT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline ODT 2.5 mg
Study: 17407630
Drug: Selegiline ODT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline ODT 1.25 mg
Study: 15342804
Drug: Tamoxifen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen plus breast irradiation (subgroup analysis for T1, receptor-positive tumors)
Study: 15342804
Drug: Tamoxifen alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen alone (subgroup analysis for T1, receptor-positive tumors)
Study: 15545529
Drug: Single RF
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single RF treatment (1 treatment)
Study: 15545529
Drug: Two RF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two RF treatments (2 treatments spaced 1 month apart)
Study: 9377992
Drug: Dipyrone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (1 g/100 ml NaCl i.v.)
Study: 9377992
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 ml NaCl i.v.)
Study: 8394864
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine with immune globulin (5 mL)
Study: 10195783
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine alone
Study: 3732422
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (30 mg/kg, once a week for 6 weeks)
Study: 3732422
Drug: Oral maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral maintenance corticosteroid therapy (not specified)
Study: 27788696
Drug: Mealtime intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mealtime intervention with weekly visits from a trained volunteer who prepared and shared a meal
Study: 8681491
Drug: F105 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: F105 (100 mg/m2)
Study: 8681491
Drug: F105 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: F105 (500 mg/m2)
Study: 8681491
Drug: F105 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: F105 (both doses)
Study: 8681491
Drug: F105 (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: F105 (bolus dose every 21 days)
Study: 6422096
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy of nonspecific and host mediate immunotherapy and chemotherapy as an adjuvant to surgery
Study: 22113220
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Group A)
Study: 24102165
Drug: GaAs laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: GaAs laser therapy (peak power 10 W; pulse frequency 3000 Hz; average power 0.012 W; wavelength 980 nm; irradiation duration 300 sec; dose 12.73 J/cm²)
Study: 17032921
Drug: Salvage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage therapy after relapse
Study: 15326083
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 to 8 mg per day)
Study: 15326083
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 to 100 mg per day)
Study: 12002730
Drug: Fexofenadine 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 360 mg
Study: 10417497
Drug: Promethazine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 30 mg
Study: 9619533
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) administration of gonadotrophins
Study: 9619533
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) administration of gonadotrophins
Study: 9619533
Drug: Both s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both s.c. and i.m. administration of gonadotrophins
Study: 7613555
Drug: Theophylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (300 mg b.i.d.)
Study: 7613555
Drug: Doxofylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxofylline (400 mg t.i.d.)
Study: 2198208
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg after the evening meal (R-P group)
Study: 6282482
Drug: ACE (Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE (Doxorubicin 45 mg/m2 i.v. day 1, Cyclophosphamide 1.0 mg/m2 i.v. day 1, VP16-213 50 mg/m2/day i.v. days 1-5)
Study: 11782042
Drug: Marginal models
Normalized name: Culex marginalis
DrugBank: Culex pipiens (DB14165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marginal models (GEE, WGEE, ML)
Study: 9059684
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg terbinafine daily for 3 months
Study: 9059684
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg terbinafine daily for 3 or 6 months
Study: 8112373
Drug: Nicorandil (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (all doses)
Study: 2873000
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with theophylline and beta-adrenergic agonist
Study: 25709055
Drug: Self-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-guided therapy
Study: 28060048
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of inactivated hepatitis A vaccine (group 1)
Study: 28060048
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of inactivated hepatitis A vaccine plus 1 dose of combined hepatitis A and B vaccine (group 2)
Study: 28060048
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of combined hepatitis A and B vaccine (group 3)
Study: 25454689
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 12 mg I.V. ibandronate on day 1 then oral ibandronate 50 mg daily (arm A)
Study: 25454689
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral therapy of 50 mg ibandronate daily from day 1 (arm B)
Study: 25454689
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 12 mg I.V. ibandronate (arm A)
Study: 23062542
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) with an implantable cardioverter‐defibrillator (ICD)
Study: 15774402
Drug: Green land-based
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Green land-based activities, training and social support; specific dosage and duration not mentioned.
Study: 15774402
Drug: Qualitative interviews
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative interviews and focus group discussions; specific dosage and duration not mentioned.
Study: 9670112
Drug: Training group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training group (n = 21) - physical training including exercises on bicycle ergometer for 30 minutes (5 times a week), overall-conditioning exercises for 30 minutes daily, and 30 to 60 minutes of walking each day.
Study: 8152756
Drug: Powder-free surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder-free surgical gloves with postoperative injections of 5-fluorouracil
Study: 3062134
Drug: Azathioprine in
Normalized name: azathioprine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine in combination with steroids
Study: 19404953
Drug: Azathioprine treatment
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine treatment
Study: 11579006
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care integrated with motivational interviewing, cognitive behavior therapy, and family intervention
Study: 8129387
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day CGS16949A
Study: 8129387
Drug: 2 mg/day
Normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/day CGS16949A
Study: 8129387
Drug: 4 mg/day
Normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/day CGS16949A
Study: 30453316
Drug: Treatment condition
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment condition (Sketch and Speak intervention)
Study: 26079469
Drug: Immediate insertion
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate insertion of contraceptive implant
Study: 26079469
Drug: Delayed insertion
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed insertion of contraceptive implant
Study: 23561463
Drug: Practical prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practical prescription information or services
Study: 23561463
Drug: Combination prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination prescription information or services
Study: 23561463
Drug: Practical prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practical prescription information or services (for subjects prescribed a drug that treats an underlying condition)
Study: 11579011
Drug: Pindolol 5
Normalized name: pindolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 5 mg t.i.d. for 4 weeks
Study: 9649259
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg testosterone via intramuscular injection once a week for 15 weeks
Study: 9649259
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg testosterone via intramuscular injection once a week for 15 weeks
Study: 9649259
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg testosterone via intramuscular injection once a week for 15 weeks
Study: 9649259
Drug: Total semen
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total semen PSA levels decreased following administration of testosterone
Study: 31401679
Drug: Cod intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod intake (750 g/week for 8 weeks)
Study: 31401679
Drug: Salmon intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon intake (750 g/week for 8 weeks)
Study: 30935953
Drug: R-pina (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-pina (375 mg/m2 rituximab plus 2.4 mg/kg pinatuzumab vedotin)
Study: 30935953
Drug: R-pola (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-pola (375 mg/m2 rituximab plus 2.4 mg/kg polatuzumab vedotin)
Study: 28077162
Drug: Fixed inhaled
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed inhaled nitrous oxide/oxygen mixture